When a Tooth Extraction Becomes a Jaw-Threatening Risk
By Kristen Pratt Machado
Originally at decisionsindentistry.com
Summary & scoring by The Bell Brief (Dr. Jennifer Bell) using the Drill-Down Protocol (Drill-Down Score) — not the original publisher.
Why it matters for dental
Medication-related osteonecrosis of the jaw (MRONJ) after routine extractions poses a direct liability and clinical risk for any dental practice; owners, oral surgeons, periodontists, and general dentists who extract teeth in patients on antiresorptive or antiangiogenic drugs must integrate risk assessment and prevention into daily workflows to avoid devastating complications and potential litigation.
Key points
- MRONJ risk is highest in oncology patients receiving high-dose IV bisphosphonates or denosumab, but also documented with lower-dose oral bisphosphonates used for osteoporosis.
- Prevention hinges on pre-extraction medical history screening, drug-holiday coordination with prescribing physicians, and use of antibiotic prophylaxis or alternative local therapies where indicated.
- Early signs include non-healing sockets, exposed bone, or fistulas; prompt referral to an oral surgeon within 7–14 days can limit progression to pathologic fracture or extensive resection.
- Decisions in Dentistry stresses that failing to document medication review and informed consent for at-risk patients elevates malpractice exposure and may affect malpractice premiums.
Who should care
Read the original on Decisions in Dentistry
Full reporting and any paywall content live on decisionsindentistry.com. We summarize and score; we do not republish.